What's affecting your health in Miami? It could be lizards, storms or your brain
These articles on Miami's health focus on environmental influences and mental health issues.
A study on lizards explores how the presence of brown anoles can disrupt mosquito feeding patterns and potentially reduce disease transmission to humans. Researchers at the University of Miami study Alzheimer's disease in Hispanic and Black communities, highlighting a personalized approach to medicine. Meanwhile, post-hurricane mental health concerns like PTSD are addressed by mental health experts advocating for cognitive therapies as a path to recovery.
NO. 1: WHAT'S WRONG WITH YOUR BRAIN? IT COULD COME DOWN TO WHAT YOU NEED MORE OF EACH NIGHT
Here is some expert medical advice. | Published June 5, 2024 | Read Full Story by Michelle Marchante
Juan Jose Muñoz (left) and Elvin Antonio Urbina walk with her belongings through the flooded N 15th St in North Tampa, Thursday, October 10, 2024, a day after Hurricane Milton crossed Florida's Gulf Coast.
NO. 2: FLORIDIAN HURRICANE SURVIVORS COULD BE SUFFERING FROM PTSD—BUT RECOVERY IS POSSIBLE
After a tumultuous hurricane season, an expert says Floridians should look out for symptoms of PTSD. | Published November 27, 2024 | Read Full Story by Denise Hruby
No image found A caretaker, center, offers cafecito to Asustina Valdes Cabrera, left, while she is tested by UHealth medical researcher Dr. Katrina Celis, right, as part of an Alzheimer study during a community outreach event for the John P. Hussman Institute for Human Genomics where UM researchers performed tests, enrolled new participants and took blood samples to a new Biorespository opening at UHealth's campus, at Hora Feliz Adult Day Care on Thursday, January 16, 2025, in Hialeah, Fla. By D.A. Varela
NO. 3: HOW A UM LAB IS UNLOCKING THE SECRETS OF THE BRAIN. IT STARTS WITH A PERSONAL MESSAGE
What to know about the visits. | Published January 24, 2025 | Read Full Story by Michelle Marchante
Peter's rock agamas have spread across Florida, in some places pushing aside native species like the brown anole. That shift in the reptile population could potentially have ripple effects on mosquitoes and the spread of diseases . By Alex Grimsley
NO. 4: HOW A TURF WAR BETWEEN LIZARDS IN FLORIDA IMPACTS MOSQUITOES AND MAYBE YOUR HEALTH
Researchers are looking at the role a tiny lizard plays in protecting us from mosquito-borne diseases | Published March 5, 2025 | Read Full Story by Denise Hruby
The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias
Next Generation Assays Provide Unique Insights into Neurofibrillary Tangles, Disease Progression, and Novel Treatments for Better Precision Medicine ST. LOUIS, July 15, 2025--(BUSINESS WIRE)--C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of two new highly anticipated plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA. C2N eMTBR-tau243 (endogenous Microtubule Binding Region) is a unique blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. C2N cites research that says this may provide the potential to improve the diagnostic evaluation of Alzheimer's pathology in clinical trials, supporting essential disease staging, predicting disease progression and response to treatment, and monitoring treatment efficacy. This new plasma assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by C2N nearly two years ago and is available for Research Use Only. C2N obtained the exclusive rights for these technologies from the Bateman Lab at WashU Medicine. With funding from the GHR Foundation, the C2N team optimized and industrialized these assays using rigorous analytical methods to bring them to their current state. The company aims to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future. C2N Increases Diagnostic Power With C2N %p-tau MAA C2N is also launching a novel p-tau multi-analyte assay (MAA). This assay uses high-resolution mass spectrometry (LC-MS/MS) to precisely quantitate six analytes related to phosphorylated and nonphosphorylated forms of tau (%p-tau181, %p-tau205 and %p-tau217). The C2N %p-tau MAA measures multiple phosphorylated tau forms from a single sample and, therefore, enables greater efficiencies. This test is likewise available for Research Use Only. C2N's LC-MS/MS methodologies enable a ratio of phosphorylated tau divided by non-phosphorylated tau (%p-tau) that previously has been shown to mitigate for confounding factors such as age and medical comorbidities like kidney disease. The Journal of the American Medical Association (JAMA) published a large clinical study that found C2N's PrecivityAD2™ test accuracy was not impacted in the primary care arm of the study despite having patients of older age and with higher prevalence of comorbidities. The company believes the C2N %p-tau MAA and C2N eMTBR-tau243 assays will play a key role in biopharma clinical trials, enabling better assessment of Alzheimer's disease pathology and supporting a precision medicine approach to novel treatment strategies. The assays will cover both early-stage and late-stage tau pathology identification, providing a robust marker for disease identification, staging, and stratification. "Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics, first as Research Use Only tools and then in the form of clinical diagnostic tests," says C2N CEO and President Dr. Joel Braunstein. "Patients and families worried about Alzheimer's disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer's disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community." The Precivity™ line of blood tests currently available clinically to aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions are: PrecivityAD®, PrecivityAD2™, and Precivity-AopE™. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit View source version on Contacts COMPANY CONTACT:Joni Hendersoninfo@ MEDIA CONTACT:Adam 202-427-3603
Business Wire
2 hours ago
- Business Wire
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias
ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of two new highly anticipated plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA. 'Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics," says C2N CEO and President Dr. Joel Braunstein. C2N eMTBR-tau243 (endogenous Microtubule Binding Region) is a unique blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. C2N cites research that says this may provide the potential to improve the diagnostic evaluation of Alzheimer's pathology in clinical trials, supporting essential disease staging, predicting disease progression and response to treatment, and monitoring treatment efficacy. This new plasma assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by C2N nearly two years ago and is available for Research Use Only. C2N obtained the exclusive rights for these technologies from the Bateman Lab at WashU Medicine. With funding from the GHR Foundation, the C2N team optimized and industrialized these assays using rigorous analytical methods to bring them to their current state. The company aims to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future. C2N Increases Diagnostic Power With C2N %p-tau MAA C2N is also launching a novel p-tau multi-analyte assay (MAA). This assay uses high-resolution mass spectrometry (LC-MS/MS) to precisely quantitate six analytes related to phosphorylated and nonphosphorylated forms of tau (%p-tau181, %p-tau205 and %p-tau217). The C2N %p-tau MAA measures multiple phosphorylated tau forms from a single sample and, therefore, enables greater efficiencies. This test is likewise available for Research Use Only. C2N's LC-MS/MS methodologies enable a ratio of phosphorylated tau divided by non-phosphorylated tau (%p-tau) that previously has been shown to mitigate for confounding factors such as age and medical comorbidities like kidney disease. The Journal of the American Medical Association (JAMA) published a large clinical study that found C2N's PrecivityAD2™ test accuracy was not impacted in the primary care arm of the study despite having patients of older age and with higher prevalence of comorbidities. The company believes the C2N %p-tau MAA and C2N eMTBR-tau243 assays will play a key role in biopharma clinical trials, enabling better assessment of Alzheimer's disease pathology and supporting a precision medicine approach to novel treatment strategies. The assays will cover both early-stage and late-stage tau pathology identification, providing a robust marker for disease identification, staging, and stratification. 'Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics, first as Research Use Only tools and then in the form of clinical diagnostic tests,' says C2N CEO and President Dr. Joel Braunstein. 'Patients and families worried about Alzheimer's disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer's disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community.' The Precivity™ line of blood tests currently available clinically to aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions are: PrecivityAD®, PrecivityAD2™, and Precivity-AopE™. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit
Newsweek
3 hours ago
- Newsweek
Flesh-Eating Virus Kills Four In Florida
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Four people have died in Florida due to infections from Vibrio vulnificus, a bacterium commonly known as "flesh-eating" for its ability to cause severe and sometimes fatal tissue damage. Newsweek has reached out to Florida's Department of Health via email for comment. Why It Matters Record cases of Vibrio vulnificus surged to record levels last year in Florida, with 82 cases and 19 deaths, Florida's health department reported at the time. The majority came after the hurricanes Helene and Milton. Flagellated Vibrio vulnificus bacterium revealed in the 26367x magnified scanning electron microscopic (SEM) image, 2005. Image courtesy Centers for Disease Control (CDC) / Janice Haney Carr. Flagellated Vibrio vulnificus bacterium revealed in the 26367x magnified scanning electron microscopic (SEM) image, 2005. Image courtesy Centers for Disease Control (CDC) / Janice Haney Carr. Smith Collection/Gado/Getty Images What To Know Fatalities have been reported across Bay, Broward, Hillsborough, and St. Johns counties, according to the Florida Department of Health, who reported the fatalities on July 11. This marks the first fatalities in connection with the bacterium this year. There have been a total of 11 confirmed infections across the state so far this year. The Florida Department of Health did not confirm the sources of these cases. What is Vibrio Vulnificus? Vibrio vulnificus is a naturally occurring bacterium found in coastal waters, including salt and brackish water. There are around a dozen kinds of Vibrio, which cause the human illness, vibriosis. The Centers for Disease Control and Prevention (CDC) estimates that there are 80,000 cases of vibriosis each year in the U.S., of which 52,000 cases are the result of eating contaminated food. The most common species that cause human illness in the U.S. are Vibrio parahaemolyticus, Vibrio vulnificus, and Vibrio alginolyticus. Thomas A. Russo, professor and chief, Division of Infectious Diseases, University of Buffalo, told Newsweek over email, "The range of Vibrio vulnificus is defined by warm, brackish, and coastal marine environments, with ongoing expansion into higher latitudes as global temperatures rise. This organism is most prevalent in regions with water temperatures above 20°C and moderate-to-high salinity." "Cases have been rising as summers have grown warmer," Aileen Marty, professor of Infectious Diseases, Florida International University, told Newsweek, "The reason is that V. vulnificus is naturally found in warm, brackish coastal waters, especially in the Gulf Coast states (e.g., Florida, Texas, Louisiana, Alabama, Mississippi)." Marty told Newsweek, "Symptoms often appear within 12–24 hours and include gastrointestinal distress, fever, blistering skin lesions, and potentially life-threatening sepsis or necrotizing fasciitis after wound exposure. Most severe cases occur in people with underlying health problems; mild or asymptomatic cases are likely underreported, as healthy individuals may experience few or no symptoms." Russo also told Newsweek, "Entry of V. vulnificus into an open wound (pre-existing or acquired while in the water) is the most common means of acquisition. Eating raw seafood is another, especially raw oysters." "Although healthy individuals can develop infection, which can be severe, individuals with chronic liver disease, hemochromatosis, diabetes mellitus, immunosuppression, and iron overload states are at higher risk for developing severe infection, which can be fatal," Russo said. What People Are Saying Thomas A. Russo, professor and chief, Division of Infectious Diseases, University of Buffalo, told Newsweek over email, "Infections can occur with the combination of environmental exposure and host-factors... If you have a wound, cut, or disruption of your skin for whatever reason (e.g. recent surgery, tattoos et al) stay out of the water (seawater or brackish water) or cover the wound if exposure cannot be avoided. If you get a cut or injury while in the water, get out asap and wash the area," Russo said. Aileen Marty, professor of Infectious Diseases, Florida International University, told Newsweek over email, "The primary transmission routes are through the ingestion of raw or undercooked shellfish, especially oysters, or exposure to brackish water through wounds. Individuals at highest risk include those with chronic liver disease (such as hepatitis B or C), diabetes, immune suppression, alcohol use disorder, malignancy, renal disease, or iron overload conditions like hemochromatosis." William Schaffner, MD, professor of Preventive Medicine, Department of Health Policy, told Newsweek over email, "The precautions are straightforward. Avoid going into the coastal water if you have broken skin. If you sustain an injury in the water, wash it off promptly and seek appropriate medical attention, particularly if the wound looks infected or the area becomes painful. Tell your provider of your water contact. Persons with chronic liver disease or who are immunocompromised should avoid eating raw oysters." What's Next Whether cases will rise this year remains to be seen.
